S-1 monotherapy versus S-1 combination therapy in gemcitabine-refractory advanced pancreatic cancer

S-1 monotherapy versus S-1 combination therapy in gemcitabine-refractory advanced pancreatic cancer

BACKGROUND Pancreatic cancer (PC) is one of the most lethal digestive system tumors. Most new cases are diagnosed based on metastasis or local aggression and are known as "advanced PC." Recently, studies investigating S-1 have indicated that it has a better clinical curative effect on PC. We conducted a meta-analysis to evaluate the efficacy and safety of S-1 monotherapy compared with S-1 combi...

Gemcitabine Compared With Gemcitabine and S-1 Combination Therapy in Advanced Pancreatic Cancer

Several reports suggest that gemcitabine (GEM) plus S-1 combination (GS) is associated to prolong the survival in patients with unresectable pancreatic cancer (PC). We conducted a systemic review and meta-analysis of studies comparing the safety and efficacy of GS versus GEM.Summary data from randomized trials and retrospective studies were searched in PubMed, EMBASE, Web of Science, and the Co...

A randomized phase II study of S-1 plus oral leucovorin versus S-1 monotherapy in patients with gemcitabine-refractory advanced pancreatic cancer†

BACKGROUND We evaluated the efficacy and toxicity of adding oral leucovorin (LV) to S-1 when compared with S-1 monotherapy in patients with gemcitabine-refractory pancreatic cancer (PC). PATIENTS AND METHODS Gemcitabine-refractory PC patients were randomly assigned in a 1:1 ratio to receive S-1 at 40, 50, or 60 mg according to body surface area plus LV 25 mg, both given orally twice daily for...

Author ' s response to reviews Title : Gemcitabine versus gemcitabine based combination chemotherapy in advanced pancreatic cancer

Biweekly gemcitabine with S-1 combination chemotherapy in locally advanced or metastatic pancreatic cancer

Objective: Gemcitabine (GEM)-based combination chemotherapy has been studied to determine whether or not it improves outcomes, but results have generally been disappointing. We retrospectively compared chemotherapy with biweekly GEM plus a novel form of an oral 5-fluorouracil derivative (S1) (GEM+S-1) with GEM alone in locally advanced or metastatic pancreatic cancer. Patients and Methods: We s...